ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dipropizine

Also written as “R1_PBK_M2301 (levodropropizine)”, “Levopront® syrup 30 mg/5 ml” and “Levotuss”.

Its studies are mostly in Cough · Bronchitis, Chronic, led by 5 companies.

Drug pageDipropizine: every studyMany companies study it; this page follows only the 5 they lead. All 6 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 6, 20105 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ache Laboratorios Farmaceuticosits history only10 open or runningphase 3since Aug 6, 2010Aug 6, 2010none ahead
Dompé Farmaceutici S.p.Aits history only10 open or runningphase 3since Jan 28, 2019Jan 28, 2019none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 1since Apr 5, 2012Apr 5, 2012none ahead
Hyundai Pharm10 open or runningphase 3since Mar 30, 2018Mar 30, 2018none ahead
Pharmbio Koreaits history only11 open or runningphase 1since Aug 20, 2025Aug 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2018First study: phase 3 study in Bronchitis, ChronicFirst studyNCT03489837 · 272 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Hyundai Pharm leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03489837Bronchitis, Chronic · Korea, Republic of3CompletedOct 2018272

How it is read

Names in the registry

  • “R1_PBK_M2301 (levodropropizine)”, 1 entry
  • “Levopront® syrup 30 mg/5 ml”, 1 entry
  • “Levotuss”, 1 entry
  • “diphenhydramine + dropropizine + pseudoephedrine”, 1 entry
  • “Ambroxol and Levodropropizine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.